SureTrader SureTrader
Home > Boards > US Listed > Biotechs > Peregrine Pharmaceuticals (PPHM)

I don't know about the rest of you,

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
pphmtoolong Member Profile
 
Followed By 23
Posts 3,010
Boards Moderated 0
Alias Born 07/17/06
160x600 placeholder
Advertisement
Peregrine Pharmaceuticals' Immuno-Oncology Agent Bavituximab to be Highlighted in Three Presentations at 2015 ASCO Annual Mee... "GlobeNewswire Inc." - 5/13/2015 5:00:00 PM
*Special Analyst Alert* and 4 Companies that are Worth a Look "InvestorsHub NewsWire" - 5/13/2015 7:00:00 AM
Preclinical Data Presented at AACR Demonstrate Synergistic Anti-Tumor Effects of Peregrine Pharmaceuticals' Phosphatidylserin... "GlobeNewswire Inc." - 4/21/2015 8:00:00 AM
Peregrine Pharmaceuticals Given a $5.00 Price Target at Roth Capital (PPHM) "Analyst Ratings Network" - 4/20/2015 3:24:37 PM
Data Presented at AACR Demonstrate Peregrine Pharmaceuticals' Bavituximab Induces Immune Activation in PD-L1 Negative NSCLC T... "GlobeNewswire Inc." - 4/20/2015 8:00:00 AM
Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2015 Annual Meeting "GlobeNewswire Inc." - 4/14/2015 8:00:00 AM
5 Promising Biotech Stocks Under $10 "The Motley Fool" - 4/3/2015 8:04:02 AM
Peregrine Pharmaceuticals Announces Promising Bavituximab Phase I Data Published in the Peer-Reviewed Journal Cancer Medicine... "GlobeNewswire Inc." - 3/31/2015 12:45:22 PM
Peregrine Pharma ups revenues 46% in FQ3 "Seeking Alpha" - 3/13/2015 7:26:55 AM
Peregrine Pharmaceuticals' (PPHM) CEO Steve King on Q3 2015 Results - Earnings Call Transcript "Seeking Alpha" - 3/12/2015 10:35:07 PM
Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2015 Financial Results and Recent Developments "GlobeNewswire Inc." - 3/12/2015 4:00:00 PM
Independent Research Initiates Analyst Coverage on Inventergy Global, Inc. (NASDAQ: INVT) with $1.20 Price Target "InvestorsHub NewsWire" - 3/12/2015 8:00:00 AM
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock "GlobeNewswire Inc." - 3/10/2015 4:00:00 PM
Peregrine Pharmaceuticals to Report Third Quarter Fiscal 2015 Financial Results After Market on March 12, 2015 "GlobeNewswire Inc." - 3/5/2015 4:00:00 PM
Peregrine Pharmaceuticals to Present at the 27th Annual ROTH Conference "GlobeNewswire Inc." - 3/2/2015 4:00:00 PM
NEW CONCEPT LAUNCHES TODAY FOR MICRO-CAP STOCK TRADERS. RECEIVE PAID PRE-PROMO STOCK ALERTS FOR FREE. "InvestorsHub NewsWire" - 2/9/2015 7:00:00 AM
ALTITRADE PARTNERS™ SAYS A KEY-REVERSAL DAY COULD HAPPEN THIS WEEK "InvestorsHub NewsWire" - 10/14/2014 6:00:00 AM
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock "Marketwired" - 6/10/2014 4:00:00 PM
pphmtoolong   Tuesday, 04/24/12 10:44:52 AM
Re: None
Post # of 220812 
I don't know about the rest of you, but I bought this stock based on Thorpe's approved patents and the early Bavi clinical studies.

It seems that Peregrine management and BOD have done everything reasonable to forward the Bavi agenda given the limited financial resources available. Running the trials overseas in Georgia and India could not have been easy, but they did it and got promising results. As in many other cases Bavi may not pan out in later stage trials. I don't blame management for trying with Bavi, and I don't blame management for the perversity of Mother Nature. I could blame them for excessive optimism, but the science seemed sound to them just as it seemed sound to us.

I don't like that managment has diluted the heck out of our stock, but I really don't buy any of the alternative financing plans I've seen presented here. I am a retired CPA; so I have some confidence assessment on this point.

If Bavi finally hits it out of the park with second line NSCLC, there is still a chance for us to make money. Otherwise, this has been a very expensive lesson in wishful thinking on biotechs. I blame only myself if Peregrine flops. I never should have thrown so much money into such a crap shoot.

Paul

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist